5kits zhao

Calendar

January 2011
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Pages

Archives

Blogroll






 

Article Date: 01 Oct 2010 – 3:00 PDT

AstraZeneca UK is delighted to announce that it has received UK approval for Seroquel XL(R) (quetiapine prolonged release) as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy. Prior to initiating treatment, clinicians should consider the safety profile of quetiapine prolonged release. The decision follows the European Commission approval earlier this month.

According to the Depression Alliance one in five people will have depression at some point in their life[i], and MDD is the leading cause of suicide particularly in people who have not received adequate treatment for their symptoms[ii]. As up to 50% of people who suffer from MDD do not respond to first-line antidepressant treatment[iii], add-on treatments are regularly used to manage this serious condition and are included in national guidelines[iv],[v]. The new indication for quetiapine prolonged release will therefore potentially benefit such people who have failed to respond to first-line treatment and who require additional therapy.

“Depression is an important public-health problem which has been shown to have a greater negative effect on health than angina, arthritis, asthma, and diabetes[vi]”, said Stuart Montgomery, Emeritus Professor of Psychiatry. “Effective medicines are a cornerstone of management for people with depression, and this new indication for quetiapine prolonged release provides healthcare professionals with a new option of add-on therapy when considering how best to treat inadequately responding MDD. This can only be good news for people who suffer from this serious and common condition.”

Read in Full:  http://www.medicalnewstoday.com/articles/203153.php



Leave a Reply

*